Advisory committee members will have to grapple with bleeding risks associated with Merck & Co. Inc.’s platelet inhibitor vorapaxar, a product once thought to be a potential blockbuster, but now likely searching for an ideal population for use.
Vorapaxar, proposed trade name Zontivity, will go before the Cardiovascular and Renal Drugs Advisory Committee Jan. 15 as part of a three-day meeting; Chelsea Therapeutics International Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?